VLS Valneva SE

VALNEVA Declaration of shares and voting rights: August 31, 2025

VALNEVA Declaration of shares and voting rights: August 31, 2025

VALNEVA

Declaration of shares and voting rights

August 31, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: September 3, 2025

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**






171,854,856



ordinary shares with a par value of €0.15 each
187,979,199Double voting rights granted on 245 ordinary shares









Transfer into bearer form of 1,125 shares with double voting rights









Capital increase without preferential subscription rights (1,666,666 new ordinary shares issued)
Between August 7 & August 25, 2025















Between August 11 & August 26, 2025















On August 28, 2025
187,854,877

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
03/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chiku...

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ® Long-lasting antibody persistence was comparable in older (65+) and younger adultsLong-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data four years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with ...

 PRESS RELEASE

Valneva annonce un taux de séroréponse de 95% quatre ans après une vac...

Valneva annonce un taux de séroréponse de 95% quatre ans après une vaccination avec une seule dose du vaccin contre le chikungunya IXCHIQ® Persistance des anticorps chez les adultes âgés de 65 ans et plus, comparable à celle des jeunes adultesLa durabilité de la réponse immunitaire est un avantage compétitif clé pour un vaccin ciblant une maladie épidémique comme le chikungunya Saint-Herblain (France), le 30 septembre 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui des données positives sur la persistance des anticorps quatre ans ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch